<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOBREX- tobramycin ointment </strong><br>Alcon Laboratories, Inc.<br></p></div>
<h1><span class="Bold">Tobrex® (tobramycin ophthalmic ointment) 0.3%</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="splSectionDescription"></a><a name="section-1"></a><p></p>
<h1>
DESCRIPTION
</h1>
<p class="First">TOBREX® (tobramycin ophthalmic ointment) 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Each gram of TOBREX® (tobramycin ophthalmic ointment) 0.3% contains: <span class="Bold">Active: </span>tobramycin 0.3% (3 mg). <span class="Bold">Preservative: </span>chlorobutanol 0.5%. <span class="Bold">Inactives: </span>mineral oil, white petrolatum.</p>
<p>Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.</p>
<p>The chemical structure of tobramycin is :</p>
<div class="Figure"><img alt="
chemical
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cdd423c5-a231-47d4-bf51-00b5c29e6a60&amp;name=chemical.jpg"></div>
<p>Molecular formula:</p>
<p>C<span class="Sub">18</span>H<span class="Sub">37</span>N<span class="Sub">5</span>O<span class="Sub">9</span></p>
<p>Molecular weight:</p>
<p>467.52</p>
<p>Chemical name:</p>
<p>0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4) }-0-{2,6-diamino-2,3,6-trideoxy-α-D-ribohexo-pyranosyl-(1→6) }-2-deoxystreptamine.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="splSectionClinicalPharmacology"></a><a name="section-2"></a><p></p>
<h1>
CLINICAL PHARMACOLOGY
</h1>
<p class="First"><span class="Italics">In Vitro Data : In vitro</span> studies have demonstrated tobramycin is active against susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms: Staphylococci, including <span class="Italics">S. aureus</span> and <span class="Italics">S. epidermidis</span> (coagulase-positive and coagulase-negative), including penicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>.</p>
<p>Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p><span class="Italics">Pseudomonas aeruginosa</span>, <span class="Italics">Escherichia coli, Klebsiella pneumoniae</span>, <span class="Italics">Enterobacter aerogenes</span>, <span class="Italics">Proteus mirabilis</span>, <span class="Italics">Morganella morganii</span>, most <span class="Italics">Proteus vulgaris</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>, <span class="Italics">Haemophilus influenzae</span> and <span class="Italics">H. aegyptius</span>, <span class="Italics">Moraxella lacunata</span>, <span class="Italics">Acinetobacter calcoaceticus</span> and some <span class="Italics">Neisseria species</span>. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="splSectionIndicationsUsage"></a><a name="section-3"></a><p></p>
<h1>
INDICATIONS AND USAGE
</h1>
<p class="First">TOBREX® (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX® (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="splSectionContraindications"></a><a name="section-4"></a><p></p>
<h1>
CONTRAINDICATIONS
</h1>
<p class="First">TOBREX® (tobramycin ophthalmic ointment) 0.3 % is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="splSectionWarnings"></a><a name="section-5"></a><p></p>
<h1>
WARNINGS
</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to TOBREX® (tobramycin ophthalmic ointment) 0.3% occurs, discontinue use.</p>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="splSectionPrecautionsGeneral"></a><a name="section-6"></a><p></p>
<h1>
PRECAUTIONS
</h1>
<p class="First"><span class="Bold">General. </span>As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be initiated. Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p>Cross-sensitivity to other aminoglycoside antibiotics may occur; if <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> develops with this product, discontinue use and institute appropriate therapy.</p>
<p>Patients should be advised not to wear contact lenses if they have signs and symptoms of ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="splSectionPrecautionsPatientInfo"></a><a name="section-6.1"></a><p></p>
<h2>
Information For Patients
</h2>
<p class="First">Do not touch tube tip to any surface, as this may contaminate the ointment.</p>
<p><span class="Bold">Do not use the product if the imprinted carton seals have been damaged, or removed.</span></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="splSectionPrecautionsPregnancy"></a><a name="section-6.2"></a><p></p>
<h2>
Pregnancy Category B
</h2>
<p class="First">Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="splSectionPrecautionsPregnancyNursing"></a><a name="section-6.3"></a><p></p>
<h2>
Nursing Mothers
</h2>
<p class="First">Because of the potential for adverse reactions in nursing infants from TOBREX® (tobramycin ophthalmic ointment) 0.3%, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="splSectionPrecautionsPediatric"></a><a name="section-6.4"></a><p></p>
<h2>
Pediatric Use
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age of 2 months has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="splSectionPrecautionsGeriatric"></a><a name="section-6.5"></a><p></p>
<h2>
Geriatric Use
</h2>
<p class="First">No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="splSectionAdverseReactions"></a><a name="section-7"></a><p></p>
<h1>
ADVERSE REACTIONS
</h1>
<p class="First">The most frequent adverse reactions to TOBREX® (tobramycin ophthalmic ointment) 0.3% are <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and localized ocular toxicity, including lid <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>. These reactions occur in less than three of 100 patients treated with TOBREX® (tobramycin ophthalmic ointment) 0.3%. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported from TOBREX® (tobramycin ophthalmic ointment) 0.3% therapy; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration. In clinical trials, TOBREX® (tobramycin ophthalmic ointment) 0.3 % produced significantly fewer adverse reactions (3.7%) than did GARAMYCIN® Ophthalmic Ointment (10.6%).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="splSectionOverdose"></a><a name="section-8"></a><p></p>
<h1>
OVERDOSAGE
</h1>
<p class="First">Clinically apparent signs and symptoms of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of TOBREX® (tobramycin ophthalmic ointment) 0.3% (<span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">punctate keratitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, increased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and lid <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>) may be similar to adverse reaction effects seen in some patients.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="splSectionDosageAdministration"></a><a name="section-9"></a><p></p>
<h1>
DOSAGE AND ADMINISTRATION
</h1>
<p class="First">In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) two or three times per day. In severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, instill a half-inch ribbon into the affected eye(s) every three to four hours until improvement, following which treatment should be reduced prior to discontinuation.</p>
<p>How to Apply TOBREX® (tobramycin ophthalmic ointment) 0.3%:</p>
<p>1. Tilt your head back.</p>
<p>2. Place a finger on your cheek just under your eye and gently pull down until a ''V'' pocket is formed between your eyeball and your lower lid.</p>
<p>3. Place a small amount (about 1/2 inch) of TOBREX® (tobramycin ophthalmic ointment) 0.3% in the ''V'' pocket. Do not let the tip of the tube touch your eye.</p>
<p>4. Look downward before closing your eye.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="splSectionHowSupplied"></a><a name="section-10"></a><p></p>
<h1>
HOW SUPPLIED
</h1>
<p class="First">3.5 g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (<span class="Bold">NDC </span>0065-0644-35), containing tobramycin 0.3% (3 mg/g).</p>
<p><span class="Bold">Storage: </span>Store at 2°- 25°C (36°- 77°F).</p>
<p><span class="Bold">Rx Only</span></p>
<p>© 2002, 2008 Alcon, Inc.</p>
<p>Revised: July 2008</p>
<p>Manufactured for:</p>
<p><span class="Bold">ALCON LABORATORIES, INC.</span></p>
<p>Fort Worth, Texas 76134 USA</p>
<p>Manufactured by:</p>
<p><span class="Bold">S.A. ALCON-COUVREUR N.V.</span></p>
<p>Puurs, Belgium</p>
<p>44280-1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="splSectionPDP"></a><a name="section-11"></a><p></p>
<h1>
PRINCIPAL DISPLAY PANEL
</h1>
<p class="First"><span class="Bold">NDC</span> 0065-0644-35  Alcon<span class="Sup">®</span></p>
<p><span class="Bold">Tobrex</span><span class="Sup">®</span></p>
<p>(tobramycin ophthalmic</p>
<p>ointment) 0.3%</p>
<p><span class="Bold">Sterile 3.5 g Net Wt.</span></p>
<div class="Figure"><img alt="
carton
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cdd423c5-a231-47d4-bf51-00b5c29e6a60&amp;name=carton.jpg"></div>
<p></p>
<div class="Figure"><img alt="
label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cdd423c5-a231-47d4-bf51-00b5c29e6a60&amp;name=label.jpg"></div>
<p>  </p>
<p>  </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOBREX 		
					</strong><br><span class="contentTableReg">tobramycin ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0644</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TOBRAMYCIN</strong> (TOBRAMYCIN) </td>
<td class="formItem">TOBRAMYCIN</td>
<td class="formItem">3 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CHLOROBUTANOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0644-35</td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050555</td>
<td class="formItem">06/28/1981</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.
							(008018525)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Alcon Laboratories, Inc. (008018525)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">S.A. ALCON-COUVREUR N.V.</td>
<td class="formItem"></td>
<td class="formItem">370205429</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2e5b10f7-9127-4dc0-84bf-0fd88b25d374</div>
<div>Set id: cdd423c5-a231-47d4-bf51-00b5c29e6a60</div>
<div>Version: 5</div>
<div>Effective Time: 20110714</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
